Background: Although antibodies to infliximab (ATI) correlate with lower serum trough levels and clinical loss of response (LOR), 10 60% of LOR patients have low infliximab trough levels in the absence of detectable ATI ("double negative status"). Whether this phenomenon reflects immunological drug elimination, non-immune clearance of infliximab or technical assay limitations is currently unclear. Objective: To evaluate the prevalence and outcome of infliximab-treated IBD patients with double negative (INF ATI ) status and to investigate the immunological mechanisms responsible for this phenomenon. Methods: Sera of infliximab-treated IBD patients were obtained prospectively between 2009 and 2013. Sera of patients with LOR were tested for drug/ATI trough levels using both the commercially available double antigen ELISA (employing labeled infliximab as the detection antibody) and anti-lambda ELISA (with anti-human lambda chain detection antibody). To increase analytical sensitivity, the anti-lambda assay was repeated with a 1:10 serum dilution in 46 randomly selected double negative sera. In addition, 30 double negative patients on anti-lambda ELISA were matched with 30 controls (INF+ATI ) and followed for subsequent development of detectable ATI and clinical outcome. Results: Using anti-lambda ELISA, only 25 out of 188 sera (13%) of patients with LOR were double negative compared to 35.5% with double antigen ELISA (27/76 sera tested, P < 0.001, Fisher exact test). When applying anti-lambda ELISA to the 27 sera which were ATI INF by the double antigen assay, only 22% remained double negative. 44% were actually infliximab positive (INF+ATI ), 30% were ATI positive (INF ATI+) and 4% were double positive (INF+ATI+). Moreover, when repeating the anti-lambda ELISA at a 1:10 dilution, 54% of the doublenegative sera became infliximab positive, 33% were double positive and 11% were ATI positive. Only one serum retained its double negativity (2%), as did all sera of healthy controls. On prospective follow up of patients with double negative sera, a higher rate of subsequent formation of non-transient ATI (OR 4.66, 95% CI 1.57 13.86, p = 0.006) and shorter survival free of non-transient ATI was observed compared with matched controls (p < 0.001). Conclusions: In many cases, double negative status results from false negative detection of infliximab or ATI by the conventional double antigen ELISA. In other cases, it arises from low drug and ATI levels, close to the detection threshold of the more sensitive anti-lambda assay. The later cases probably reflect a transitional state of immunological equilibrium between exogenous infliximab and endogenous ATI, rather than a state of non immunological drug clearance.
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The use of faecal calprotectin in IBD and reducing unnecessary colonoscopy Background: Faecal calprotectin (FC) are capable of differentiating between organic and functional bowel disease with a 93% sensitivity and 96% specificity. Where the diagnosis is unclear, FC can be used to spare unnecessary invasive colonoscopy. Functional symptoms are said to occur in 60% of ulcerative colitis (UC) and 40% of Crohn's disease patients. This can create a difficult management dilemma, which in turn can lead to both over, and under, treatment of presumed flares in the patients with inflammatory bowel disease. Methods: Over a 6 month period FC data was collected from known IBD patients, where a colonoscopy was being considered because of diagnostic uncertainty about whether they were suffering from organic or functional (IBS) symptoms. A normal, borderline and high result was recorded when levels were <50, 50 100 and >100 mg/g, respectively. A retrospective review was performed to assess the diagnostic and management outcome. Results: In the IBD patients colonoscopy was spared in 84% (37/44), including 13/14 with normal FC, 8/9 with borderline FC and 16/21 with high FC. In the IBD cohort the FC changed management in 10/14 with normal results, 4/9 with borderline results and 16/21 with high results. Conclusions: With the increasing demand being made on colonoscopy units throughout UK, a greater utilization of faecal calprotectin into general clinical practice could help safely relieve some of this burden. This can be used to help maintain adequate endoscopy waiting times, whilst also lightening the financial burden for the Clinical Commisioning Groups. Many hospitals are now adopting FC testing into their IBS investigation and referral pathways for general practitioners, prior to them considering referrals to the hospital based gastroenterology specialists. In known IBD patients Faecal Calprotectin assessments spared 84% of colonoscopy, as both negative and positive result directly influenced subsequent management. We believe this is an incredibly useful test in helping to provide clinicians the confidence to focus on treating functional bowel symptoms and tailor down escalating management regimes in those with normal result.
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The Modified Mayo Endoscopic Score (MMES): a new score for the assessment of extent and severity of endoscopic activity in ulcerative colitis (UC) patients Background: Complete mucosal healing (MH) has become a major endpoint in clinical trials. However, in Crohn's disease, partial mucosal healing has also been associated with a better long-term outcome. Since current endoscopic activity scores for ulcerative colitis (UC) do not take into account the extent and distribution of mucosal inflammation, the effect of partial MH in UC has not been assessed. As a first step, we developed a simple score for UC endoscopic activity, taking into account extent and distribution of mucosal inflammation. Methods: During endoscopy, the colon was divided into five segments and for each one the operator reported the Mayo endoscopic subscore. The Mayo endoscopic subscores for each segment separately were added to give a Modified Score (MS). The Extended Modified Score (EMS) was obtained by multiplying the MS by the maximal extent of inflammation (in decimeters). The Modified Mayo Endoscopic Score (MMES) was obtained by dividing the EMS with the number of segments with active inflammation (excluding cecal patch). Biopsies were obtained from rectum and sigmoid, as well as from all inflamed segments. Clinical activity was scored according to Mayo partial score and symptomatic remission was defined as Mayo stool frequency of 0 1 and Mayo rectal bleeding of 0. Biological activity was scored according to C-reactive protein (CRP) and fecal calprotectin (FC). Histological activity was scored according to the Geboes' score (GS). Cutt-off values for activity were CRP 5 mg/dL, FC 250 mg/g and GS 3.1 (presence of neutrophils in the epithelium).
Results: 98 UC patients from 2 hospitals were included (median (IQR) age 47 (36 56) years and median disease duration 11 (5 21) years). As shown in Tables 1 and 2 , all evaluated endoscopic scores correlated well with Mayo partial score, CRP, FC and GS. Of note, mean MMES scores were significantly different for patients with and without clinical, biological and histological activity. The area under the curve to predict histological activity was 0.86, 0.82, 0.83 and 0.84 for Mayo, MS, EMS and MMES respectively. Conclusions: Correlations between the MMES scores and clinical, biological and histological activity were as good as those with the Mayo endoscopic subscore. A longitudinal analysis assessesing the accuracy of evolution in MMES scores to predict long-term response to treatment is ongoing.
